Biointron Weekly Reports
News?
Thank you to all those who came to meet us at the Festival of Biologics at Messe Basel last week! It was a pleasure to chat with you, and our experts Nina Sun and Leon (Shunteng) Shi are more than happy for you to reach out with any further questions. ?
This Week’s Headlines
- The first FDA-approved anti-NGF monoclonal antibody has been launched for dogs with osteoarthritis.?
- FDA approves Opdivo (nivolumab), a fully human IgG4 monoclonal antibody to PD-1 as an adjuvant in resected stage IIB/C melanoma.?
- Novel mouse anti-NOX5 monoclonal antibody detects NOX5 protein in normal human tissues for the first time.?
- A human monoclonal antibody, 9H2,?with the potential to treat poliovirus, neutralizing all three serotypes.?
Trends?
Monoclonal antibodies in the US veterinary market are growing, and so is the willingness of pet owners to spend on their furry companions. ?
On January 13, 2022, the first monoclonal antibody (mAb) drug?for an animal was approved by the FDA. The drug, Solensia (frunevetmab injection), was approved for cats to control pain?from osteoarthritis. Frunevetmab is a cat-specific mAb designed to recognize and attach to a nerve growth factor (NGF), which is involved in pain regulation, thus preventing the pain signal from reaching the brain.?
Fast forward to today, when Zoetis has just launched the first FDA-approved mAb therapy for dogs with Librela (bedinvetmab injection). It is the first and only anti-NGF mAb treatment to control canine osteoarthritis pain, helping to improve the mobility and quality of life for dogs affected.?
Cats and dogs can be affected by chronic conditions such as cancer, arthritis, allergies, and chronic pain. Antibody treatments, similar to those for humans, could help. But unlike chemical drugs that can be adapted for pets, most antibodies are species-specific, so if given to pets, can trigger immune responses and side effects. Thus, antibodies designed specifically for animals are needed. ?
While the market for expensive therapies in cats and dogs is much smaller than the market for human therapeutics, there is a growing perception of pet owners being willing to spend more to treat their furry companions. An April 2023 survey by Ally Consumer Research reports that 51% of pet owners would take on debt to care for their pets’ healthcare needs, with 44% up to $4,999 and 22% at least $5,000 or more, despite rising inflation. This is reinforced from the?pet ownership boom during?COVID, with the average US annual household spending on pets rising from $460 in 2013 to $770 in 2021. ?
?
领英推è
Upcoming Events?
We have two conferences coming up next month! The Society for Immunotherapy of Cancer (SITC) is holding the 38th Annual Meeting on November 1-5 in San Diego, CA, with the option to join virtually. Don’t miss the chance to visit our booth in person and hear from leading keynote speakers, view poster presentations, and engage in networking opportunities.??
Next, we will be attending the 15th Annual PEGS Europe: Protein & Antibody Engineering Summit on November 14-16! The event will be located in the Lisbon Congress Center in Portugal. This year’s conference has a record attendance and will be the largest PEGS Europe ever, so be sure to come by!?
Promotions?
Our AbExplorers promotion season is ongoing! Take advantage of these offers from now through the end of the year and accelerate your research projects. Visit our website or contact our team for more details and claim your discount.?
- 10% off discovery and optimization services?
- 25% off referral expression services?
- 40% off all Abinvivo catalog products?
New Products?
Learn more about Biointron at www.biointron.com, or contact us at info@biointron.com and +1 (732) 515-4766.